Patent ID: 7192922

Claim:
A method for treating a human patient with heart failure due to left ventricular (LV) systolic dysfunction with an LV ejection fraction less than 40% comprising administering for 72 hours or more to said human patient, a compound selected from the group consisting of GIP, GIP analogs, GIP derivatives and pharmaceutically-acceptable salts thereof, GLP-1, GLP-1analogs, GLP-1 derivatives and pharmaceutically-acceptable salts thereof, at a rate of administration of the compound of between 1 and 20 pmol/kg/min to improve the following LV functions: LV ejection fraction (LVEF); stroke volume (SV); LV end-systolic volume (LVESV); global wall motion score index (g-WMSI); and infarct zone wall motion score index (IZ-WMSI).